Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Colorectal Neoplasms

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    July 2022
  1. SINICROPE FA
    The Increasing Incidence of Early-Onset Colorectal Cancer. Reply.
    N Engl J Med. 2022;387:93-94.
    PubMed    


  2. GOLDSTEIN MR, Mascitelli L
    The Increasing Incidence of Early-Onset Colorectal Cancer.
    N Engl J Med. 2022;387:93.
    PubMed    


  3. WOLOSHIN S, Kramer BS
    The Increasing Incidence of Early-Onset Colorectal Cancer.
    N Engl J Med. 2022;387:91-93.
    PubMed    


    June 2022
  4. SANOFF HK
    Improving Treatment Approaches for Rectal Cancer.
    N Engl J Med. 2022;386:2425-2426.
    PubMed    


  5. CERCEK A, Lumish M, Sinopoli J, Weiss J, et al
    PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
    N Engl J Med. 2022;386:2363-2376.
    PubMed     Abstract available


  6. PALEFSKY JM, Lee JY, Jay N, Goldstone SE, et al
    Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.
    N Engl J Med. 2022;386:2273-2282.
    PubMed     Abstract available


  7. TIE J, Cohen JD, Lahouel K, Lo SN, et al
    Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMoa2200075.
    PubMed     Abstract available


  8. MONTAGUT C, Vidal J
    Liquid Biopsy for Precision Adjuvant Chemotherapy in Colon Cancer.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMe2204625.
    PubMed    


    April 2022
  9. SINICROPE FA
    Increasing Incidence of Early-Onset Colorectal Cancer.
    N Engl J Med. 2022;386:1547-1558.
    PubMed    


    February 2022
  10. DOUBENI CA, Corley DA, Zhao W, Lau Y, et al
    Association between Improved Colorectal Screening and Racial Disparities.
    N Engl J Med. 2022;386:796-798.
    PubMed    


  11. MIN A, Ditkofsky N
    Page Kidneys.
    N Engl J Med. 2022;386:673.
    PubMed    


    January 2022
  12. HORN DM, Haas JS
    Expanded Lung and Colorectal Cancer Screening - Ensuring Equity and Safety under New Guidelines.
    N Engl J Med. 2022 Jan 8. doi: 10.1056/NEJMp2113332.
    PubMed    


    June 2021
  13. AWAD MM, Liu S, Rybkin II, Arbour KC, et al
    Acquired Resistance to KRAS(G12C) Inhibition in Cancer.
    N Engl J Med. 2021;384:2382-2393.
    PubMed     Abstract available


    March 2021
  14. ROUSSEAU B, Foote MB, Maron SB, Diplas BH, et al
    The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.
    N Engl J Med. 2021;384:1168-1170.
    PubMed    


  15. DIAZ LA JR, Le DT, Andre T
    Microsatellite-Instability-High Advanced Colorectal Cancer. Reply.
    N Engl J Med. 2021;384:972-973.
    PubMed    


  16. SORSCHER S
    Microsatellite-Instability-High Advanced Colorectal Cancer.
    N Engl J Med. 2021;384:972.
    PubMed    


  17. BATTISTUZZI L, Puccini A, Sciallero S
    Microsatellite-Instability-High Advanced Colorectal Cancer.
    N Engl J Med. 2021;384:971-972.
    PubMed    


    December 2020
  18. GROTHEY A
    Pembrolizumab in MSI-H-dMMR Advanced Colorectal Cancer - A New Standard of Care.
    N Engl J Med. 2020;383:2283-2285.
    PubMed    


  19. ANDRE T, Shiu KK, Kim TW, Jensen BV, et al
    Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    N Engl J Med. 2020;383:2207-2218.
    PubMed     Abstract available


    November 2020
  20. LU KH, Broaddus RR
    Endometrial Cancer.
    N Engl J Med. 2020;383:2053-2064.
    PubMed    


    September 2020
  21. HONG DS, Fakih MG, Strickler JH, Desai J, et al
    KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors.
    N Engl J Med. 2020;383:1207-1217.
    PubMed     Abstract available


  22. BURKE CA, Dekker E, Lynch P, Samadder NJ, et al
    Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
    N Engl J Med. 2020;383:1028-1039.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: